南财智讯12月15日电，华兰生物公告称，公司参股公司华兰基因工程有限公司近日收到国家药监局签发 的地舒单抗注射液境内生产药品注册上市许可申请《受理通知书》。规格为120mg（1.7ml）/瓶，申请 人为华兰基因工程有限公司。该药品为治疗用生物制品3.3类。 ...

华兰生物公告，近日，公司参股公司华兰基因工程有限公司收到国家药品监督管理局签发的地舒单抗注 射液境内生产药品注册上市许可申请《受理通知书》。地舒单抗注射液为生物类似药，其原研产品由安 进公司开发，已在全球多个国家及地区获批上市，用于治疗骨质疏松症、骨巨细胞瘤等多类骨骼疾病。 地舒单抗通过特异性靶向核因子κB受体活化因子配体（RANKL）发挥作用，强效抑制破骨细胞介导的 骨吸收和骨破坏，从而有效预防和延迟骨相关事件的发生。 ...

目前国内已有江苏泰康生物医药有限公司、齐鲁制药有限公司、山东博安生物技术股份有限公司、康宁 杰瑞(吉林)生物科技有限公司四家公司的地舒单抗注射液获批上市，若基因公司获批上市，将丰富基因 公司的产品梯队，为基因公司增加新的利润增长点。 地舒单抗是一种人源化单克隆抗体(IgG2型)，通过特异性靶向核因子κB受体活化因子配体(RANKL)发 挥作用。RANKL是破骨细胞形成、发挥功能和存活所必需的关键因子。恶性肿瘤骨转移常导致骨溶解 性破坏，引发骨痛、病理性骨折、脊髓压迫、高钙血症等骨相关事件，严重影响患者生活质量和生存预 后。地舒单抗通过抑制RANKL，强效抑制破骨细胞介导的骨吸收和骨破坏，从而有效预防和延迟上述 骨相关事件的发生，是临床重要的肿瘤支持治疗药物。 格隆汇12月15日丨华兰生物(002007.SZ)公布，近日，公司参股公司华兰基因工程有限公司(以下简称"基 因公司")收到国家药品监督管理局签发的地舒单抗注射液境内生产药品注册上市许可申请《受理通知 书》(受理号：CXSS2500138)。 公司研发的地舒单抗注射液为生物类似药。其原研产品由安进公司开发，已在全球多个国家及地区获批 上市，用于治疗骨质疏 ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-046 华兰生物工程股份有限公司 关于参股公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，公司参股公司华兰基因工程有限公司（以下简称"基因公司"）收到 国家药品监督管理局签发的地舒单抗注射液境内生产药品注册上市许可申请《受 理通知书》（受理号：CXSS2500138）。现将相关情况公告如下： 一、申请注册药品的基本情况 药品名称：地舒单抗注射液 申请事项：境内生产药品注册上市许可 注册分类：治疗用生物制品 3.3 类 规 格：120mg（1.7ml）/瓶 药品适应症：实体肿瘤骨转移和多发性骨髓瘤、骨巨细胞瘤 结 论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 申请人：华兰基因工程有限公司 二、药品相关情况简介 公司研发的地舒单抗注射液为生物类似药。其原研产品由安进公司开发，已 在全球多个国家及地区获批上市，用于治疗骨质疏松症、骨巨细胞瘤等多类骨骼 疾病，其疗效与安全性获得了广泛临床验证。 地舒单抗是一种人源化单克隆抗体（IgG ...

Group 1: Macro and Market Overview - The financial data for November shows a recovery due to increased fiscal efforts, with social financing growth supported by accelerated government bond issuance and faster conversion of fiscal spending into general deposits [2] - A favorable liquidity environment is highlighted, with significant growth in corporate bond financing contributing positively to social financing [2] - The A-share market is expected to perform well in the upcoming year-end, supported by ongoing domestic economic policy efforts and historical trends indicating strong performance in the first year of the 13th and 14th Five-Year Plans [3] Group 2: Bond Market Insights - The secondary market for REITs has seen a decline in prices, with the weighted REITs index closing at 180.06 and a weekly return of -0.23% [5] - Credit bond issuance increased significantly, with 369 bonds issued totaling 459.51 billion yuan, a 35.34% increase from the previous period [6] - Investors are advised to adopt a comprehensive view when analyzing financial aggregate data, focusing on a balanced understanding of the market [4] Group 3: Industry-Specific Research - In the float glass industry, the trend of increasing concentration among leading companies is expected to continue, with recommendations to focus on Xinyi Glass and Qingdao Huadong Glass [10] - The photovoltaic glass sector is anticipated to see a clearing out of smaller companies at the industry cycle's bottom, leading to increased concentration among leading firms, with a focus on Xinyi Solar and Flat Glass Group [10] - The banking sector is experiencing a slowdown in credit expansion, with social financing in November at 2.5 trillion yuan, maintaining an 8.5% growth rate [11] Group 4: Company-Specific Analysis - Zhongyou Engineering has successfully launched a new material project, with projected net profits of 738 million yuan, 825 million yuan, and 929 million yuan for 2025-2027, respectively [20] - The company is rated as "buy" due to its strategic expansion into emerging business areas [20] - Hualan Biological is increasing its investment in innovative products and has a high dividend payout ratio, enhancing its long-term investment value [22]

Group 1: Healthcare Sector Insights - The new medical insurance directory and the first commercial insurance innovative drug directory have been released, emphasizing both expansion and quality improvement to support the high-quality development of innovative drugs [3][4]. - The success rate of negotiations for the medical insurance directory reached 88%, the highest in seven years, while the commercial insurance directory included 19 innovative drugs with a negotiation success rate of 79% [4]. - The approval rate for drugs outside the directory is 41.48%, indicating a strict evaluation process, while the renewal rate for negotiated drugs within the directory is as high as 75% [4]. Group 2: Investment Opportunities in Pharmaceuticals - Companies such as Heng Rui Medicine, BeiGene, Innovent Biologics, and CanSino Biologics are recommended for attention due to their focus on "true innovation" and "differentiated innovation" in the context of the dual directory collaboration [4]. - Huazhong Bio (002007.SZ) is increasing its investment in vaccine development, innovative drugs, and biosimilars, with a cash dividend of 7 yuan per 10 shares (including tax) and a dividend yield of 4.63% [10]. Group 3: Glass Industry Analysis - The float glass industry is seeing a trend of increasing concentration among leading companies, with a recommendation to focus on Xinyi Glass and Qibin Group [12]. - The photovoltaic glass sector is expected to clear out a number of small and medium enterprises at the industry cycle's bottom, leading to a significant increase in concentration among leading firms, similar to the float glass industry [12]. Group 4: Financial Data Overview - In November, financial data showed a recovery due to increased fiscal spending, with new social financing reaching 2.5 trillion yuan, maintaining an 8.5% growth rate [26]. - The M2 money supply growth remained stable, while M1 growth declined further, indicating a shift in the credit structure towards short-term loans [26]. Group 5: Investment in Debt Instruments - The low interest rate environment is expected to enhance the attractiveness of fixed-income assets, making bond ETFs a favorable investment opportunity [28]. - The Guotai Shanghai 10-Year Treasury ETF (511260.SH) is highlighted for its large scale, good liquidity, and favorable risk-return ratio, suggesting a strong trend towards public funds as core asset allocations [28]. Group 6: Robotics and Automation Sector - The company Geekplus (2590.HK) is recognized as a global leader in the AMR warehouse sector, with a strong commercial capability and a significant global presence [30]. - The company is expected to see revenue growth from 3.16 billion yuan in 2025 to 5.12 billion yuan in 2027, with a projected price-to-sales ratio lower than comparable companies [30].

Group 1 - The core viewpoint of the article highlights the steady growth of the blood products business and a significant increase in demand for quadrivalent influenza vaccines [4][5] Group 2 - As of mid-2025, the company operates 34 plasma collection stations, with 4 stations expected to exceed 100 tons of plasma collection in 2024, indicating strong growth potential in the blood products sector [4] - The company has seen a rapid consumption of quadrivalent influenza vaccines due to increased public awareness and demand from health authorities, leading to multiple batch applications for market release [4] Group 3 - The company is actively investing in innovation, focusing on process upgrades and new product development in blood products, as well as advancing research in vaccines, innovative drugs, and biosimilars [5] - Specific advancements include the completion of on-site verification for a new 10% intravenous immunoglobulin product, plans for submitting a Pre-IND for subcutaneous immunoglobulin, and ongoing Phase III clinical trials for coagulation factor IX [5] Group 4 - The company has implemented a cash dividend of 7 yuan per 10 shares for 2025, resulting in a dividend yield of 4.63% based on the closing price on December 11, 2025, emphasizing its commitment to stable and predictable cash dividends [6]

Core Insights - The flu season in 2025 is more severe than in the past three years, with higher reported cases across both northern and southern China according to the CDC [1] - Despite a surge in sales of flu medications, the vaccination rate for flu vaccines in China remains low, particularly among the 18-59 age group [1][6] - In contrast, Chile has achieved a high vaccination rate of 85% among key populations, highlighting a significant disparity in public health responses [5][7] Group 1: Flu Season Overview - The CDC reported an increase in flu-like cases, with 1219 outbreaks recorded, predominantly caused by the H2N3 strain [1] - In Guangdong, the flu-like cases accounted for 11.90% of emergency visits, significantly higher than previous weeks [2] - The flu season in Guangdong is expected to peak around mid-December, with hospitals managing the increase in patients effectively [2][4] Group 2: Vaccination Rates and Challenges - The vaccination rates in China are alarmingly low, with only 0.52% for the 18-59 age group and 4.63% for those over 60, far below the WHO's recommended 75% coverage [6] - In contrast, Chile has a well-established vaccination program, with free vaccines available to a clearly defined target population, leading to higher uptake [7][9] - The Chinese public exhibits vaccine hesitancy, influenced by misconceptions about vaccine safety and effectiveness [4][12] Group 3: Comparison with Chile - Chile's vaccination strategy includes a long history of public health campaigns and a focus on vulnerable populations, which has resulted in high vaccination rates [7][9] - The accessibility of vaccination sites in Chile, including schools and community centers, contrasts with China's more limited options [11] - Effective communication about vaccine benefits and managing public expectations are crucial in reducing vaccine hesitancy, as observed in both countries [12]

Investment Rating - The report maintains a "Buy" rating for the company, considering its innovative layout and high dividend yield [3][4]. Core Insights - The blood products business is expected to maintain steady growth, with a significant increase in demand for quadrivalent influenza vaccines. By mid-2025, the company will have 34 plasma collection stations, with four stations expected to exceed 100 tons of plasma collection in 2024 [1]. - The company is actively innovating in the blood products sector, upgrading existing processes and developing new products. This includes the completion of on-site verification for a new 10% intravenous immunoglobulin and plans for a subcutaneous immunoglobulin submission [2]. - The company has implemented a cash dividend of 7 yuan per 10 shares for 2025, resulting in a dividend yield of 4.63% based on the closing price on December 11, 2025. The company aims to enhance the stability and predictability of its cash dividends [3]. Summary by Sections Blood Products Business - The blood products segment is projected to grow steadily, supported by an increase in plasma collection and improved utilization rates. The demand for quadrivalent influenza vaccines has surged, leading to faster inventory turnover [1]. Innovation and R&D - The company is increasing its R&D investments in vaccines, innovative drugs, and biosimilars. Key developments include the advancement of a recombinant herpes zoster vaccine and mRNA vaccines for influenza and respiratory syncytial virus [2]. Financial Performance and Forecast - The company has adjusted its net profit forecasts for 2025 and 2026 to 1.252 billion yuan and 1.472 billion yuan, respectively, reflecting a decrease of 20% and 23% from previous estimates. The projected earnings per share (EPS) for 2025 is 0.69 yuan, with corresponding price-to-earnings (P/E) ratios of 22, 19, and 16 for 2025, 2026, and 2027 [3][8].

（文章来源：证券日报） 证券日报网讯 12月11日，华兰生物在互动平台回答投资者提问时表示，公司将进一步提升互动易回复 频率，加强与投资者的沟通。 ...